A Retrospective, Longitudinal Registry Study on the Long-Term Durability of Ivacaftor Treatment in People with Cystic Fibrosis.

Autor: Merlo C; Division of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, 1830 E. Monument Street 5 Floor, Baltimore, MD, 21205, USA. cmerlo@jhmi.edu., Thorat T; Vertex Pharmaceuticals Incorporated, Boston, MA, USA., McGarry LJ; Vertex Pharmaceuticals Incorporated, Boston, MA, USA., Scirica CV; Vertex Pharmaceuticals Incorporated, Boston, MA, USA., DerSarkissian M; Analysis Group, Inc., Los Angeles, CA, USA., Nguyen C; Analysis Group, Inc., Los Angeles, CA, USA., Gu YM; Analysis Group, Inc., Los Angeles, CA, USA., Muthukumar A; Analysis Group, Inc., Los Angeles, CA, USA., Healy J; Vertex Pharmaceuticals Incorporated, Boston, MA, USA., Rubin JL; Vertex Pharmaceuticals Incorporated, Boston, MA, USA., Brookhart MA; Duke University, Durham, NC, USA.

Publikováno v: Pulmonary therapy [Pulm Ther] 2024 Dec; Vol. 10 (4), pp. 483-494. Date of Electronic Publication: 2024 Sep 12.

Impact of age at ivacaftor initiation on pulmonary outcomes among people with cystic fibrosis.

Autor: Merlo CA; Johns Hopkins School of Medicine, Baltimore, Maryland, USA cmerlo@jhmi.edu., McGarry LJ; Vertex Pharmaceuticals Incorporated, Boston, Massachusetts, USA., Thorat T; Vertex Pharmaceuticals Incorporated, Boston, Massachusetts, USA., Nguyen C; Analysis Group Inc, Los Angeles, California, USA., DerSarkissian M; Analysis Group Inc, Los Angeles, California, USA., Muthukumar A; Analysis Group Inc, Menlo Park, California, USA., Healy J; Vertex Pharmaceuticals Incorporated, Boston, Massachusetts, USA., Brookhart MA; Duke University, Durham, North Carolina, USA., Rubin JL; Vertex Pharmaceuticals Incorporated, Boston, Massachusetts, USA.

Publikováno v: Thorax [Thorax] 2024 Sep 18; Vol. 79 (10), pp. 915-924. Date of Electronic Publication: 2024 Sep 18.

Reduced use of erythropoiesis-stimulating agents and intravenous iron with ferric citrate: a managed care cost-offset model

Autor: Mutell R, Rubin JL, Bond TC, Mayne T

Publikováno v: International Journal of Nephrology and Renovascular Disease, Vol 2013, Iss default, Pp 79-87 (2013)

Richard Mutell, Jaime L Rubin, T Christopher Bond, Tracy Mayne DaVita Clinical Research, Minneapolis, MN, USA Background: Ferric citrate (FC) is a phosphate binder in development for the treatment of hyperphosphatemia in patients with end-stage renal

Externí odkaz: https://doaj.org/article/ddcd1d1ec32149c99fcce25432177777

Elexacaftor/tezacaftor/ivacaftor projected survival and long-term health outcomes in people with cystic fibrosis homozygous for F508del.

Autor: Lopez A; Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, MA 02210, USA. Electronic address: Andrea_Lopez@vrtx.com., Daly C; Vertex Pharmaceuticals (Europe) Limited, 2 Kingdom Street, London, W2 6BD, UK., Vega-Hernandez G; Vertex Pharmaceuticals (Europe) Limited, 2 Kingdom Street, London, W2 6BD, UK., MacGregor G; Department of Respiratory Medicine, NHS Greater Glasgow and Clyde, Glasgow Royal Infirmary, 84 Glasgow Street, Glasgow, G4 0SF, UK., Rubin JL; Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, MA 02210, USA.

Publikováno v: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society [J Cyst Fibros] 2023 Jul; Vol. 22 (4), pp. 607-614. Date of Electronic Publication: 2023 Feb 26.

MSR6 Modeling Survival of People with Cystic Fibrosis (PWCF) Aged ≥6 Years Heterozygous for the F508DEL Mutation with a Minimal Function Mutation (F/MF) in Brazil Treated with Elexacaftor/Tezacaftor/Ivacaftor and Ivacaftor (ELX/TEZ/IVA)

Autor: Pedra, G, Daly, C, Pinto, LA, Lopez, A, Vega-Hernandez, G, Rubin, JL

Publikováno v: In Value in Health July 2022 25(7) Supplement:S518-S518